John McHutchison

Chief Executive Officer & President, Director at Assembly Biosciences, Inc.

John McHutchison

John McHutchison

Chief Executive Officer & President, Director at Assembly Biosciences, Inc.

Overview
Career Highlights

Assembly Biosciences, Inc.

RelSci Relationships

865

Number of Boards

2

Birthday

1958

Age

61

Number of Awards

1

Relationships
RelSci Relationships are individuals John McHutchison likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Assembly Biosciences, Inc.

Relationship likelihood: Strong

Co-Founder & Chief Executive Officer at Oxford BioTherapeutics Ltd.

Relationship likelihood: Strong

Former Chief Medical Officer & Vice President, Research & Development at Ventrus Biosciences, Inc.

Relationship likelihood: Strong

General Counsel, Senior Vice President of Legal Operations, Corporate Secretary at Assembly Biosciences, Inc.

Relationship likelihood: Strong

Senior Vice President, Chief Scientific Officer Microbiome at Assembly Biosciences, Inc.

Relationship likelihood: Strong

Executive Vice President & Chief Scientific Officer of Virology Operations at Assembly Biosciences, Inc.

Relationship likelihood: Strong

Chief Executive Officer & Managing Partner at Oxford Capital Partners LLP

Relationship likelihood: Strong

Co-Founder at CryptoMedix, Inc.

Relationship likelihood: Strong

Founder at EUSA Pharma, Inc.

Relationship likelihood: Strong

President & Director at Synergie Lyon Cancer

Relationship likelihood: Strong

Paths to John McHutchison
Potential Connections via
Relationship Science
You
John McHutchison
Chief Executive Officer & President, Director at Assembly Biosciences, Inc.
Education

Established in 1853, the University of Melbourne is a public-spirited institution that makes distinctive contributions to society in research, learning and teaching and engagement. It’s consistently ranked among the leading universities in the world, with international rankings of world universities placing it as number 1 in Australia and number 34 in the world (Times Higher Education World University Rankings 2013-2014).

Career History
Chief Scientific Officer & Head of Research & Development
2010 - 2019

Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. In 25 years, Gilead has become a leading biopharmaceutical company with a portfolio of 15 marketed products, a growing pipeline of investigational drugs and approximately 5,000 employees in offices across four continents. Gilead's therapeutic areas of focus include HIV/AIDS, hepatitis, serious respiratory, cardiovascular, and metabolic conditions, cancer and inflammation

Associate Director
Prior

Duke Clinical Research Institute manufactures medical and botanical products. It offers specialized patient databases and clinical and operational expertise. The firm accelerates the development of therapies, diagnostics, and medical devices to humans. The company was founded in 1969 and is headquartered in Durham, NC.

Professor
Prior

Duke University Medical Center is a premier center for medical education, clinical care and biomedical research. The university offers a variety of doctor of medicine degrees and dual degree programs. It also offers an unique curriculum for M.D. students, with an entire year dedicated to research or work towards a second degree.   The university also offers graduate health professions programs, graduate programs in biomedical science and PhD programs. Duke University Medical Center was established in 1930 and is governed by the Duke University Board of Trustees.

Boards & Committees
Chief Executive Officer & President, Director
2019 - Current

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.

Non-Executive Director
2017 - Current

Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom.

Public Holdings
Restricted data only for RelSci Professional users.
Awards & Honors
2018
Order of Australia
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by John McHutchison. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of John McHutchison's profile does not indicate a business or promotional relationship of any kind between RelSci and John McHutchison.